Abstract
Gliflozins have been introduced into clinical practice as antidiabetic agents improving glucose control by increasing glycosuria due to inhibition of sodium glucose co-transporter in the proximal renal tubules. Early studies have indicated that in addition to glucose-lowering effects, decrease of body weight and blood pressure gliflozins also have significant positive effects in patients with heart failure, cardiovascular complications and diabetic kidney disease.
In this paper, we summarize current knowledge on the effects of gliflozins in patients with heart failure and kidney disease demonstrated by recently concluded randomized trials. We discuss possible differences among gliflozins available on the market, their current position in the treatment guidelines and further perspectives of their use in diabetology, cardiology and nephrology.